Whitehawk Therapeutics
Business Services · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2 Headquarters Plz Bldg 11TH Fl 11, Morr...Phone Number
(551) 321-2234Website
www.whitehawktx.comRevenue
-Stock Symbol
WHWKIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Whitehawk Therapeutics
Whitehawk Therapeutics is an antibody drug conjugate (ADC)-focused oncology therapeutics company that employs an agile and pragmatic strategy to drug development. We start with established tumor biology targets and match them with advanced technologies to develop improved therapies for high-potential cancer indications with significant patient opportunities. By employing forward-looking trial designs, we aim to swiftly demonstrate value.Explore more
Whitehawk Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Whitehawk Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Whitehawk Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Whitehawk Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Whitehawk Therapeutics
Product Launch: Get notified when Whitehawk Therapeutics launches new products
Check if Whitehawk Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Whitehawk Therapeutics has new funding data
Click to see if Whitehawk Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Whitehawk Therapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Whitehawk Therapeutics as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Whitehawk Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Whitehawk Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Whitehawk Therapeutics.
Whitehawk Therapeutics financials insights
Gather financial insights about Whitehawk Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Stock/Share Issuance
$87.5M
Most Recent Scoops
Person-Based
Stake & Stock Ownership, Finance, Tax
Project
Whitehawk Therapeutics has engineered HWK-007 with a multi-layered differentiation strategy, incorporating a high-affinity, strongly internalizing anti-PTK7 antibody with an attenuated Fc region to limit inflammatory cell uptake and reduce ILD risk, Carbon Bridge Cysteine Re-pairing conjugation chemistry for best-in-class ADC stability, PEG-based masking to extend ADC half-life, a proprietary triple alanine-based cleavage system releasing a less heme-toxic exatecan analog, and a DAR6 configuration, with trials currently clearing doses at 2 and 4 mg/kg and potential to dose up to 8 to 12 mg/kg in humans.
Pharmaceuticals
Project
presented preclinical data at AACR demonstrating a highest non-severely toxic dose (HNSTD) of 60 mg/kg across all three ADCs on its platform, a level considered relatively high within the ADC field, supporting confidence in the platform's potential therapeutic index and tolerability profile.
Pharmaceuticals
Project
Whitehawk Therapeutics is advancing HWK-007, a PTK7-directed ADC, in Phase I across non-small cell lung cancer, ovarian cancer, and endometrial cancer indications, with a 2 mg/kg cohort already enrolled and a 4 mg/kg cohort currently enrolling. The program targets an efficacy bar of approximately 40% overall response rate (ORR) in lung cancer and approximately 50% ORR in gynecological cancers, with tolerability expectations including heme-sparing effects and relatively low rates of grade 3 adverse events.
Funding
Funding
Whitehawk Therapeutics News & Media
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a Target in Second- or Later-Line EGFR NSCLC Findings Reinforce the Scientific Rationale for HWK-007, Whitehawk's Next-Generation PTK7-Directed ADC Currently in Phase 1 Development...Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
Former Incyte Executive Brings Extensive Oncology, Corporate Strategy, Business Development and Medical Affairs Experience MORRISTOWN, N.J., Sept. 10, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced...Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
MORRISTOWN, N.J., Sept. 2, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today...Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Whitehawk Therapeutics
Sign Up For FreeTo access detailed company insights
Whitehawk Therapeutics is an antibody drug conjugate (ADC)-focused oncology therapeutics company that employs an agile and pragmatic strategy to drug development. We start with established tumor biology targets and match them with advanced technologies to develop improved therapies for high-potential cancer indications with significant patient oppo... Read More
